• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech's subsidiary Vetiqure AB signs agreements with three AniCura clinics

Scandinavian ChemoTech's subsidiary Vetiqure AB signs agreements with three AniCura clinics

Report this content

The agreement between Vetiqure AB and three AniCura clinics is regarding a collaboration for TSE treatment of soft tissue sarcoma in dogs.

Through this agreement, Vetiqure AB has started a collaboration with three AniCura clinics, two in Sweden and one in Norway with the aim of studying the outcome of treatment with the company's Tumour Specific Electroporation, TSE ™, for soft tissue sarcoma in dogs. The project is run by Lic. veterinarian Nanna Åkerlund Denneberg, oncology specialist in dog and cat at AniCura Animal Hospital Jönköping. Also participating is Lic. veterinarian Marianne Jensen Mandelin, small animal specialist with a master in Oncology - dog and cat at AniCura Jeløy Animal Hospital in Moss and Lic. veterinarian Gunilla Kastengren, oncology specialist in dogs and cats at AniCura Animal Hospital Albano in Stockholm. The date for the study start is currently not set.


“It feels positive that we are expanding our relationship with more AniCura clinics in Scandinavia and thus give more veterinarians and clinicians access to our TSE-technology. A successful trial will generate a significant impact on our ability to establish a new standard of care for our animals."- says Mohan Frick, CEO of Scandinavian ChemoTech AB


For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.




Documents & Links